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Abstract
Background and Aims—A greater understanding of cholestatic disease is necessary to 
advance diagnostic tools and therapeutic options for conditions such as primary biliary cirrhosis 
(PBC) and primary sclerosing cholangitis (PSC). The purpose of this study was to determine and 
compare the serum metabolomes of patients with PBC (n=18) or PSC (n=21) and healthy controls 
(n=10) and to identify metabolites that may differentiate these two cholestatic diseases.
Methods and Results—Using a mass spectrometry-based, non-targeted biochemical profiling 
approach we identified 420 serum metabolites, 101 that differed significantly (p≤0.05) between 
PBC and control groups, 115 that differed significantly between PSC and control groups, and 56 
that differed significantly between PSC and PBC groups. Random forest classification analysis 
was able to distinguish patients with PBC or PSC with 95% accuracy with selected biochemicals 
reflective of protein and amino acid metabolism identified as the major contributors. Metabolites 
related to bile acid metabolism, lipid metabolism, inflammation, and oxidative stress/lipid 
peroxidation were also identified as differing significantly when comparing the disease groups and 
controls, with some of these pathways differentially affected in the PBC and PSC groups.
Conclusion—In this study identified novel metabolic changes associated with cholestatic 
disease that were both consistent and different between PBC and PSC. Validation studies in larger 
patient cohorts are required to determine the utility of these biochemical markers for diagnosis and 
therapeutic monitoring of patients with PBC and PSC.
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Introduction
Impaired hepatic production and excretion of bile, resulting in dramatic accumulation of 
circulating bile acids, form the basis for cholestatic liver disease. Toxins/drugs, gall stones, 
local tumors, genetic alterations, autoimmune disorders, and pregnancy, amongst other 
etiologies, may contribute to reductions in bile flow associated with cholestasis (1–3). 
Response to hepatobiliary injury ranges from proliferation of cholangiocytes and 
hepatocytes to development of periductular fibrosis, biliary fibrosis, and cirrhosis (4), 
ultimately giving rise to end-stage liver disease and the need for liver transplantation. In 
general, pathogenic mechanisms of cholestatic disease are poorly understood; therefore, 
clinical management of these complex disorders remains quite limited (5).
Two similar but distinct cholestatic diseases include primary biliary cirrhosis (PBC) and 
primary sclerosing cholangitis (PSC). PBC is an autoimmune disease in which progressive 
lymphocytic inflammation leads to destruction of intrahepatic bile ducts, and is 
predominantly observed in asymptomatic, middle-aged women (6). PSC is characterized by 
chronic inflammation of the biliary epithelium resulting in destruction of intra- and 
extrahepatic bile ducts, and is typically diagnosed in middle-aged males with a high 
preponderance of concurrent inflammatory bowel disease (7). Currently, differential 
diagnosis of PBC and PSC is sometimes complicated by overlapping clinical, serological, 
histological, and radiological findings and the overall lack of standardized diagnostic and 
treatment criteria (8). In addition, ursodeoxycholic acid (UDCA) is currently the only 
available therapy for cholestatic liver disease but several new investigational drugs are under 
evaluation for either PBC (Obeticholic acid, NCT01473524) or PSC (simtuzumab, 
NCT01672853). With the regulatory approval and eventual availability of these agents, a 
definitive diagnosis will be critical. Moreover, identification of a metabolic profile that 
would identify responders versus non-responders may provide an opportunity to personalize 
use of these therapeutic products.
Due to their downstream location within the biological spectrum, small molecules (ranging 
from 99–1000 Da) represent integration of various upstream processes (i.e., genetics, 
transcriptomics, and proteomics) and are often very closely related to phenotype (9). In 
order to gain insight into the pathogenesis of PBC and PSC and identify potential 
biomarkers to distinguish these two related disorders, we utilized a screening approach to 
profile the global metabolome (10) of serum samples from patients with PBC or PBC and 
healthy controls. Aside from a previous report in which 17 serum bile acids were profiled in 
serum from PBC and PSC patients (11), this is the first study to define and compare the 
global serum metabolomes of patients with PBC and PSC and to explore utilization of small 
molecule profiles to differentiate between the two groups.
Patients and Methods
Patients
Serum samples were obtained from a local blood bank (healthy controls) or from an ongoing 
liver bio bank at Indiana University. Liver bio bank was approved by the Indiana University 
Institutional Review Board and all participants signed an informed consent that allows 
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archived serum and liver tissue samples to be used for future research purposes. Serum 
samples were prepared immediately after their acquisition and were frozen at −80°C until 
the metabolomic studies were conducted.
Metabolic profiling
Sample preparation—The non-targeted metabolic profiling platform employed for this 
analysis combined three independent platforms: ultrahigh performance liquid 
chromatography/tandem mass spectrometry (UHPLC/MS/MS) optimized for basic species, 
UHPLC/MS/MS optimized for acidic species, and gas chromatography/mass spectrometry 
(GC/MS). Samples were processed essentially as described previously (10, 12). For each 
sample, 100µL of serum was used for analyses. Using an automated liquid handler 
(Hamilton LabStar, Salt Lake City, UT), protein was precipitated with methanol that 
contained four standards to report on extraction efficiency. The resulting supernatant was 
split into equal aliquots for analysis on the three platforms. Aliquots, dried under nitrogen 
and vacuum-desiccated, were subsequently either reconstituted in 50µL 0.1% formic acid in 
water (acidic conditions) or in 50µL 6.5mM ammonium bicarbonate in water, pH 8 (basic 
conditions) for the two UHPLC/MS/MS analyses or derivatized to a final volume of 50µL 
for GC/MS analysis using equal parts bistrimethyl-silyl-trifluoroacetamide and solvent 
mixture acetonitrile:dichloromethane:cyclohexane (5:4:1) with 5% triethylamine at 60°C for 
one hour. In addition, three types of controls were analyzed in concert with the experimental 
samples: aliquots of a well-characterized human plasma pool served as technical replicates 
throughout the data set, extracted water samples served as process blanks, and a cocktail of 
standards spiked into every analyzed sample allowed instrument performance monitoring. 
Experimental samples and controls were randomized across two platform run days.
LC/MS/MS and GC/MS—For UHLC/MS/MS analysis, aliquots were separated using a 
Waters Acquity UPLC (Waters, Millford, MA) and analyzed using an LTQ mass 
spectrometer (Thermo Fisher Scientific, Inc., Waltham, MA) which consisted of an 
electrospray ionization (ESI) source and linear ion-trap (LIT) mass analyzer. The MS 
instrument scanned 99–1000 m/z and alternated between MS and MS2 scans using dynamic 
exclusion with approximately 6 scans per second. Derivatized samples for GC/MS were 
separated on a 5% phenyldimethyl silicone column with helium as the carrier gas and a 
temperature ramp from 60°C to 340°C and then analyzed on a Thermo-Finnigan Trace DSQ 
MS (Thermo Fisher Scientific, Inc.) operated at unit mass resolving power with electron 
impact ionization and a 50–750 atomic mass unit scan range.
Metabolite identification—Metabolites were identified by automated comparison of the 
ion features in the experimental samples to a reference library of chemical standard entries 
that included retention time, molecular weight (m/z), preferred adducts, and in-source 
fragments as well as associated MS spectra, and were curated by visual inspection for 
quality control using software developed at Metabolon (13). At the time of this writing, 
more than 4000 commercially-available purified standard compounds were included in the 
reference library.
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Statistical analysis—For statistical analyses and data display purposes, any missing 
values were assumed to be below the limits of detection and these values were imputed with 
the compound minimum (minimum value imputation). Statistical analysis of log-
transformed data was performed using “R” (http://cran.r-project.org/), which is a freely 
available, open-source software package. Welch’s two-sample t-tests were used to compare 
differences among groups. Classification by principal component analysis and unsupervised 
hierarchal clustering was carried out using Array Studio (V5.0). Classification by the 
unbiased and supervised random forest technique, providing an estimate of the ability to 
classify individuals, was carried out between groups using the R-package “RandomForest.” 
Briefly, a set of classification trees, based on continual sampling of the experimental units 
and compounds, was created and each observation was classified based on the majority 
votes from all classification trees. Identified drug metabolites contained within the 
xenobiotic pathway were not included in the RF classification scheme. P-values ≤0.05 were 
considered statistically significant and p-values <0.10 were reported as trends. Multiple 
comparisons were accounted for by estimating the false discovery rate (FDR) using q-values 
(14).
Results
Patient characteristics
A total of 49 subjects were included in this serum metabolic profiling study. Characteristics 
of the 18 patients with PBC, 21 patients with PSC, and 10 healthy control subjects, 
including demographics and liver biochemistries, are summarized in Table 1. Consistent 
with the established gender predispositions, the PBC group was predominantly female 
(94%) while the PSC group was predominantly male (76%). Additional characteristics such 
as age, Caucasian race, and body mass index (BMI) were generally well-matched across the 
cholestatic disease and healthy control groups. Statistical comparisons of liver 
biochemistries and additional biochemical parameters revealed significantly higher (p-
value<0.05) levels of alkaline phosphatase and serum total protein in the PBC and PSC 
groups as compared to healthy controls, with non-significant elevations in alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin. Additional 
parameters such as serum albumin and serum creatinine were not different between the liver 
disease and healthy control groups, and the international normalized ratio (INR) and model 
for end-stage liver disease (MELD) scores were not different when comparing the PBC and 
PSC groups. It is important to note that the majority of PBC and PSC patients were 
receiving UDCA therapy (78% and 76%, respectively), and that a small subset of cholestatic 
patients were also taking anti-hyperlipidemic medications (33% of the PBC group and 10% 
of the PSC group). Administration of these medications has the potential to affect metabolic 
pathways highlighted in this report, including bile acid, cholesterol, and lipid metabolism.
Metabolic Profiling
Findings from the global serum metabolomic analysis are summarized in Figure 1 and a list 
of all identified metabolites, grouped by super- and sub pathways, their changes when 
comparing among groups, and p- and q-values are provided as Supplementary Table 1. 
Overall, 420 metabolites were identified and, of these, 101 differed significantly (p≤0.05) 
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when comparing PBC and control groups, 115 differed significantly when comparing PSC 
and control groups, 56 differed significantly when comparing PSC and PBC groups, and 4 
differed significantly across all three comparisons (Figure 1). Directionality of these changes 
(i.e., biochemicals that were increased or decreased) is reported in Table 2. In addition to 
significant changes, trending (0.05<p<0.10) changes were also considered and a summary of 
the numbers and direction of these changes is included in Table 2. Although the number of 
subjects taking lipid-lowering medications was too low for meaningful comparisons, 
patients with PBC or PSC who were taking UDCA were compared to those not receiving 
therapy. In general, the number of statistically significant changes when comparing patients 
receiving UDCA to those not taking UDCA within the PBC (Δ=23) and PSC (Δ=29) groups 
was roughly equivalent to the number of changes that would be expected by random chance 
alone (5 changes for every 100 metabolites). Results from these comparisons are included 
within Supplementary Table 1.
Classification Analyses
Utilization of global metabolic profiles for classification of control subjects and patients by 
disease type was determined by principal component analysis (PCA), random forest analysis 
(RF), and unsupervised hierarchal clustering. As shown in Figure 2A, results from the PCA 
demonstrate that control subjects were quite distinguishable from those with cholestatic 
disease, but that a substantial amount of overlap was present when differentiating patients 
with PBC and PSC. However, control subjects and patient groups were readily identified by 
RF analysis, which gave an overall predictive accuracy of 94% when differentiating between 
all three study groups (Figure 2B). Similarly, classification of only the PBC and PSC groups 
by RF gave an identical overall predictive accuracy of 95% as well (Figure 2C). RF 
produces a list of biochemicals ranked by their importance to the classification scheme, and 
the top 30 metabolites identified for each analysis are displayed in Figures 2B and 2C. 
Metabolites involved in amino acid/protein metabolism (including fibrinogen cleavage 
peptides), lipid metabolism (including eicosanoids, sterol metabolism, and bile acids), 
glucose metabolism, nucleotide metabolism, and xenobiotics were identified as contributing 
to the separation of groups and many of these biochemicals are discussed in more detail in 
this report. Of note, 22 common biochemicals were included in both RF importance plots. 
As shown in Supplementary Figure 1, unsupervised hierarchal clustering resulted in limited 
grouping of healthy control samples with extensive overlap observed between the two liver 
disease groups.
Pathway Analyses
Further consideration of significant biochemical changes identified several metabolic 
pathways that were differentially affected in patients with PBC or PSC as compared to 
healthy controls. As shown in Figure 3, significant elevations in several bile acids were 
observed in the liver disease groups as indicated by both p≤0.05 and q≤0.10 when 
comparing the PBC or PSC groups and healthy controls. For example, higher levels of the 
conjugated primary bile acids glycocholate, taurocholate, glycochenodeoxycholate, and 
taurochenodeoxycholate were present in patients with PBC or PSC. Similarly, significant 
elevations were noted in the unusual trihydroxy bile acid hyocholate, as well as its 
conjugated derivatives, glycohyocholate and taurohyocholate, in patients with liver disease. 
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Finally, while the secondary bile acid deoxycholate and its glycine- and taurine-conjugated 
derivatives were not different when comparing patients with liver disease and controls, 
greater than 23-fold elevations were observed in glycoursodeoxycholate and 
tauroursodeoxycholate in the PBC and PSC groups. Although UDCA is synthesized 
endogenously, these large increases in PBC and PSC patients also reflect exogenous 
administration of this bile acid as a treatment for cholestatic disease. Indeed, higher levels of 
glycoursodeoxycholate and tauroursodeoxycholate were identified in PBC and PSC patients 
taking UDCA as compared to those not receiving this therapy. As bile acids are the primary 
route for excretion of cholesterol from the body, it is also important to note the significant 
elevation (p≤0.05 and q≤0.10) in circulating cholesterol in both PBC and PSC patients as 
compared to controls.
Alterations in biochemicals related to lipid metabolism were also observed in patients with 
cholestatic disease as compared to healthy controls (Figure 4). Despite unchanged levels of 
the lipolysis marker glycerol, consistent elevations (p≤0.05 and q≤0.10) in many free fatty 
acids, including the essential fatty acids linoleate (18:2n6) and linolenate (18:3n3 or 6) and 
the long-chain unsaturated fatty acids palmitoleate (16:1n7) and oleate (18:1n9), were noted 
in the PBC and PSC groups. As summarized in Table 3, both the number of trending 
(0.05<p<0.10) or significant (p≤0.05) changes as well as the magnitude of those changes 
was slightly more pronounced in patients with PBC as compared to PSC . In addition to 
changes in free fatty acids, significant elevations in the ketone bodies acetoacetate and 3-
hydroxybutyrate (BHBA), as well as several acylcarnitines, including stearoylcarnitine, 
were also noted in the PBC and PSC groups, respectively, as compared to controls. It is 
important to note that administration of UDCA had a profound effect on circulating free 
fatty acid and ketone body levels, but this was only observed within the PSC group 
(Supplementary Table 1).
As displayed in Figure 5, several metabolites that serve as biochemical markers of 
inflammation and oxidative stress were altered in patients with PBC or PSC as compared to 
controls. For example, serum levels of the tryptophan degradation product kynurenine and 
the arachidonate-derived eicosanoid 12-hydroxyeicosatetraenoic acid (HETE) were altered 
in the PBC and PSC groups, suggestive of an inflammatory signature in these patients. 
Similarly, increased levels of the linoleate-derived product of lipid peroxidation 13-
hydroxyoctadecadienoic acid (HODE) + 9-HODE, the marker of oxidative stress and pro-
apoptotic metabolite 7β-hydroxycholesterol, and the free radical scavenger biliverdin were 
observed in PBC patients and increased levels of dimethylarginine (SDMA + ADMA) and 
biliverdin, along with altered antioxidant (vitamin C and vitamin E) metabolism, was 
observed in PSC patients.
Finally, substantial changes with regard to protein and amino acid metabolism were 
observed in patients with PBC and PSC (Table 4). In particular, levels of several free amino 
acids (serine, aspartate, glutamate, phenylalanine, and ornithine) and 9 dipeptides were 
significantly (p≤0.05) lower in patients with PSC as compared to PBC. Moreover, 
significant elevations in three fibrinogen cleavage peptides, produced when fibrinogen is 
cleaved by thrombin for blood clot formation, were also observed in the PSC as compared to 
PBC group.
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Discussion
Although metabolomic profiling has been used extensively for biomarker identification and 
informational studies involving many other liver diseases, particularly hepatocellular 
carcinoma (15) and drug-induced liver injury (16), to the best of our knowledge this study is 
the first to investigate the global serum metabolome of PBC and PSC. Here, we observed 
important differences in the serum metabolic profiles of patients with PBC or PSC as 
compared to healthy controls and, as a result, potential biomarker candidates for 
differentiating PBC from PSC were also identified. While clinical diagnosis of PBC is 
relatively straightforward, PSC presents a greater challenge without the use of endoscopic 
retrograde cholangiopancreatography (ERCP) or magnetic resonance 
cholangiopancreatography (MRCP). In addition, a serological hallmark that is present in 
PBC but not PSC includes the antimitochondrial antibody (AMA), an autoantibody that is 
found in 90–95% of PBC patients and less than 1% of normal controls (17–19). In the 
current study, differences in the serum metabolome were identified when comparing PBC 
and PSC patients and classification analyses demonstrated that, in general, the two disease 
states were quite distinguishable. In particular, predictive accuracy of the RF analyses, 
including classification of the PBC and PSC groups only, was high at 94–95% and analysis 
of the biochemical importance plots generated from both RF analyses revealed that 
metabolites reflective of protein metabolism (i.e., dipeptides and fibrinogen cleavage 
peptides) appear to have the greatest power in differentiating groups. Additional 
differentially-altered pathways with metabolites able to distinguish among groups were also 
identified when comparing patients with PBC or PSC and these findings are discussed in 
more detail below.
By definition, circulating levels of bile acids are increased in cholestatic disorders such as 
PBC and PSC as a result of biliary injury and hepatocyte accumulation of bile acids (3). In 
the current study, elevations in unconjugated, conjugated, and sulfated bile acids were 
observed in both liver disease groups, with minor changes in secondary bile acids derived 
from the gut microbiome. This pattern of change is mostly in agreement with the previous 
report by Trottier et al. demonstrating that the pathology of PBC and PSC mainly affects 
primary bile acids (11). One finding of particular interest included a significant elevation in 
serum hyocholate, an unusual trihydroxy bile acid synthesized by hydroxylation of 
chenodeoxycholate (20), in both PBC and PSC patients as compared to controls. Hyocholate 
has been found to be elevated in urine from bile acid-loaded adults (20) and children with 
Byler disease (21) and may therefore act as a biomarker of cholestasis and the ability of the 
liver to metabolize bile acids to their secretory forms. Indeed, hyocholate was the only bile 
acid included within the random forest importance plot as contributing to the separation of 
the control and liver disease groups.
Also of interest with regard to bile acid metabolism, circulating levels of cholesterol were 
significantly elevated in serum from both PBC and PSC patients. Perturbations in 
cholesterol homeostasis have been commonly associated with chronic cholestatic diseases 
(22). Changes in serum cholesterol are related to altered bile acid production through 
mechanism(s) that involve, at least to some extent, genetic, transcriptional, translational, and 
posttranslational modifications of hepatic cytochrome P450 7A1 (CYP7A1) expression/
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activity (23–25). On a related note, serum levels of the oxidized cholesterol derivatives 7-α-
hydrocholesterol (bile acid precursor) and 7-β-hydroxycholesterol (marker of lipid oxidation 
and cytotoxic, pro-apoptotic lipid mediator) and the steroid hormone cortisol were elevated 
in only the PBC group. Although 7-α-hydroxycholesterol is not an accurate systemic 
indicator of hepatic bile acid synthesis (26), and cortisol can be derived from exogenous 
administration, these differential changes may be indicative of greater lipid peroxidation and 
potential abnormalities of the pituitary-adrenal axis in patients with PBC. These key 
differences observed when comparing the two cholestatic groups may point to specific 
metabolic alterations that contribute to the pathogenesis of PBC but not PSC.
While abnormalities in lipoprotein and cholesterol metabolism have been well-described in 
patients with cholestatic disease (22), investigation into changes in circulating free fatty 
acids and hepatic β-oxidation is quite limited (27). In the current study, although consistent 
elevations in serum free fatty acids were observed in both PBC and PSC patients as 
compared to controls, increases were slightly more pronounced in the PBC as compared to 
the PSC group. This finding may be attributable to the fact that PSC patients receiving 
UDCA therapy (76% of the PSC group) exhibited lower levels of circulating free fatty acids 
as compared to those not taking UDCA. As serum levels of the lipolysis marker glycerol 
were unchanged in the PBC and PSC groups, the observed changes in free fatty acids may 
be reflective of alterations in hepatic lipid metabolism as opposed to increased release from 
adipose tissue stores. Indeed, similar elevations in the ketone bodies acetoacetate and 
BHBA, along with modest accumulation of several medium- and long-chain acylcarnitines, 
were observed in both liver disease groups despite lower circulating levels of ketone bodies 
in PSC patients taking UDCA as compared to those not receiving therapy. Ketones are 
synthesized within the mitochondrial matrix from acetyl-CoA in a pathway that shares 
several steps with the cholesterol biosynthetic pathway. Therefore, these changes may be 
indicative of a general increase in activity of the mevalonate and ketogenesis pathways in 
both liver disease groups. However, mitochondrial dysfunction is known to play a key role 
in cholestatic disease (28) and is typically associated with impaired fatty acid β-oxidation. 
Thus, accumulation of acylcarnitines and ketone bodies in patients with PBC and PSC may 
instead be suggestive of reduced fatty acid oxidation and ketogenesis, resulting in increased 
circulating free fatty acids as well as decreased peripheral utilization of ketones by target 
tissues such as brain and cardiac muscle. Support for this hypothesis comes from previous 
studies demonstrating a central role for impaired ketogenesis in altered hepatic lipid 
metabolism observed in cholestatic rats following bile duct ligation (29, 30).
Inflammation and oxidative stress are known to contribute to the pathogenesis of cholestatic 
diseases including PBC and PSC (7, 28, 31). In the current study, a similar inflammatory 
signature was observed in both the PBC and PSC groups, with elevations in the tryptophan-
derived metabolite kynurenine and reductions in the lipooxygenase-derived eicosanoid 12-
HETE. The majority of tryptophan is degraded in the liver by the enzyme tryptophan 
dioxygenase (TDO), but this amino acid can also be metabolized by the highly inducible 
enzyme indoleamine 2,3-dioxygenase (IDO) that is stimulated by pro-inflammatory 
cytokines such as interferon-γ and tumor necrosis factor-α (32). Arachidonate-derived 
products of the lipid-peroxidating enzyme 12/15-lipoxygenase, including 12-HETE, 
generally possess anti-inflammatory properties to counteract pro-inflammatory responses 
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(33). Therefore, higher levels of kynurenine and reductions in 12-HETE are suggestive of a 
systemic inflammatory signature that is similar in patients with PBC and PSC. Conversely, 
while elevations in various biochemical markers of oxidative stress were observed in both 
the PBC and PSC groups, differential changes in specific metabolites reflective of an 
oxidative environment were noted when comparing the two groups. For example, the 
oxysterol 7β-hydroxycholesterol, which is formed by autooxidation of cholesterol and is a 
specific marker of endogenous oxidative stress and lipid peroxidation, and the lipoxygenase-
derived metabolite 13-HODE + 9-HODE, which also serves as a lipid peroxidation marker, 
were only elevated in the PBC group. In contrast, levels of asymmetric dimethylarginine 
(ADMA), which are elevated when oxidative stress increases the activity of arginine 
methylating enzymes (i.e., protein arginine N-methyltransferases) and decreases the activity 
of the ADMA-degrading enzyme dimethylarginine dimethylaminohydrolase (34), were 
increased only in patients with PSC. These findings suggest that while greater oxidative 
stress is present in both cholestatic diseases, the source(s) and pathways behind this change 
may differ between PBC and PSC.
Differential changes in metabolites related to protein and amino acid metabolism were also 
observed when comparing patients with PBC and PSC and several of these were identified 
as key biochemicals with regard to the RF classification scheme. In particular, levels of 
many free amino acids and dipeptides were lower in the PSC as compared to the PBC group. 
Reports in the literature corroborate findings from the current study demonstrating 
perturbations in protein and amino acid metabolism in cholestatic disease, including 
differential changes in the plasma amino acid profile of patients with PBC and PSC (35). 
For example, administration of alanine (significantly reduced in both the PBC and PSC 
groups in the current study) was shown to reduce bilirubin levels and improve symptoms in 
three patients with end-stage PBC (36), while reductions in circulating tyrosine levels 
(which were not significantly altered in the current study) may be related to greater fatigue 
and reduced quality of life in patients with PBC (35). In addition, increased protein 
degradation and inefficient protein synthesis are among the mechanisms associated with 
malnutrition in cholestatic liver disease (37), although it is important to note that in the 
current study levels of serum total protein were significantly greater in the PBC and PSC 
groups as compared to healthy controls . Together with the current study, findings from 
these previous investigations highlight an important role for changes in protein and amino 
acid metabolism in the cholestatic disease process.
Despite the small number of subjects profiled in this descriptive study and the inclusion of 
patients taking UDCA and/or anti-hyperlipidemic medications, novel perturbations in the 
global serum metabolome were identified in patients with PBC and PSC and this 
information was successfully utilized to classify cholestatic patients and healthy controls. In 
addition to common changes in patients with cholestatic disease, findings from this study 
also identified alterations in lipid metabolism, oxidative stress/lipid peroxidation, stress 
hormones, and protein/amino acid metabolism that differed when comparing the PBC and 
PSC groups. These differential changes may not only have diagnostic value with regard to 
identifying patients with PBC versus PSC, but also provide insight into differential 
metabolic pathways that contribute to the pathogenesis of these similar conditions. 
Moreover, identification of a novel therapeutic effect of UDCA on the serum free fatty acid 
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profile was limited to the PSC group and is worthy of additional investigation. Metabolic 
profiling of an independent set of serum samples from cholestatic patients and healthy 
controls will be necessary to validate findings from this pilot study and determine the true 
diagnostic utility of biomarker candidates identified in the current study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
PBC Primary Biliary Cirrhosis
PSC Primary Sclerosing Cholangitis
UDCA Ursodeoxycholic acid
Da Dalton
UHPLC Ultrahigh performance liquid chromatography
MS Mass spectrometry
GC Gas chromatography
FDR False discovery rate
ALT Alanine aminotransferase
AST Aspartate aminotransferase
INR International normalized ratio
MELD Model for end-stage liver disease
HETE Hydroxyeicosatetraenoic acid
HODE Hydroxyoctadecadienoic acid
DMA Dimethylarginine
ERCP Endoscopic retrograde cholangiopancreatography
MRCP Magnetic resonance cholangiopancreatography
AMA Antimitochondrial antibody
CYP Cytochrome P450
TDA tryptophan dioxygenase
IDO indoleamine 2,3-dioxygenase;
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Keypoints
• The current study compares the global serum metabolomes of patients with PBC 
and PSC.
• Metabolites reflective of protein metabolism appear to have the greatest power 
in differentiating between PBC and PSC.
• Inflammatory signature (elevations in the tryptophan-derived metabolite 
kynurenine and reductions in the lipooxygenase-derived eicosanoid 12-HETE) 
was observed in both the PBC and PSC.
• Levels of several free amino acids (serine, aspartate, glutamate, phenylalanine, 
and ornithine) and 9 dipeptides were significantly (p≤0.05) lower in patients 
with PSC as compared to PBC.
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Figure 1. 
Summary of significant biochemical changes (out of 420 identified metabolites) when 
comparing among groups. Numbers of significant changes (p≤0.05) when comparing across 
the PBC, PSC, and healthy control groups, in addition to the numbers of subjects within 
each of the study groups, are displayed.
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Figure 2. 
Utilization of global metabolic profiles for classification of control subjects and patients by 
disease type by principal component analysis (PCA) and random forest analysis (RF). 
Results from the PCA (Panel A) demonstrated that healthy control subjects (HC; clear 
circles) were quite distinguishable from those with cholestatic disease, but that a substantial 
amount of overlap was present when differentiating patients with PBC (light grey circles) 
and PSC (dark grey circles). Classification of all three study groups (Panel B) or the two 
liver disease groups (Panel C) by RF gave overall predictive accuracies of 94% and 95% 
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(inset confusion matrices), respectively, and 22 common metabolites (designated by#) were 
identified within the biochemical importance plots generated from the RF analyses. 
Importance plots display both rank of metabolites according to the contribution of each to 
the classification scheme (mean decrease accuracy) and biochemical pathway identifications 
(red=amino acid, orange=carbohydrate/energy, yellow=cofactors and vitamins, green=lipid, 
blue=nucleotide, and pink=peptide).
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Figure 3. 
Differential bile acid levels in patients with PBC or PSC as compared to healthy controls. 
Boxplots convey the spread of the data with the middle 50% of the data represented by 
shaded box and the maximum and minimum values (unless there are extreme values) shown 
by the whiskers. Extreme values are defined as those that exceed, in either direction, 1.5 
times the interquartile range. The solid bar across the box represents the median value while 
the + shows the mean. For each biochemical, data are median scaled with the median value 
across all samples set equal to 1.0; thus, the y-axis reflects scaled intensity for each 
metabolite. All displayed bile acids were significantly greater (as indicated by both p≤0.05 
and q≤0.10) in the PBC and PSC groups as compared to healthy controls.
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Figure 4. 
Changes in metabolites related to lipid metabolism in the PBC and PSC groups. In addition 
to increased serum free fatty acid levels (Table 3), significant (p≤0.05) elevations in ketone 
bodies and acylcarnitines were also observed in the cholestatic disease groups as compared 
to controls. *p≤0.05 vs. control
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Figure 5. 
Alterations in biochemical markers of inflammation and oxidative stress in patients with 
PBC or PSC. Metabolites related to inflammation (Panel A) and oxidative stress (Panel B) 
that exhibited trending (0.05<p<0.10) or significant (p≤0.05) changes when comparing PBC 
and/or PSC patients to controls are displayed. *p≤0.05 vs. control; #0.05<p<0.10 vs. control
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Table 1
Clinical characteristics and liver biochemistries of study participants.
Primary Biliary
Cirrhosis (n=18)
Primary Sclerosing
Cholangitis (n=21)
Control
(n=10)
Demographics
Age (years) 49 ± 10 52 ± 16 45 ± 15
Female (%) 94 24 40
Caucasian (%) 89 95 90
BMI (kg/m2) 30 ± 7 34 ± 8 30 ± 6
Hypertension (%) 28 19 N/A
Diabetes (%) 22 5 N/A
IBD (%) 0 71 N/A
Medications
Anti-hyperlipidimics (%) 33 10 N/A
Ursodeoxycholic acid (%) 78 76 N/A
Liver Biochemistries
ALT (U/L) 96 ± 154 65 ± 48 17 ± 7
AST (U/L) 136 ± 327 57 ± 28 23 ± 3
Alk P (U/L)¶ 231 ± 117 249 ± 234 58 ± 15
Total Bilirubin (mg/dL) 1.5 ± 2.3 1.4 ± 1.1 0.5 ± 0.2
Other parameters
Serum albumin (mg/dL) 3.7 ± 0.6 3.6 ± 0.5 4.0 ± 2.3
Serum total protein (mg/dL) ¶ 7.5 ± 1.4 7.6 ± 0.7 6.3 ± 0.3
INR 1.0 ± 0.1 1.2 ± 0.5 N/A
Serum creatinine (mg/dL) 0.8 ± 0.2 0.9 ± 0.3 0.9 ± 0.1
MELD score 8.1 ± 2.8 10.6 ± 3.8 N/A
All values are expressed in mean ± standard deviation unless otherwise mentioned.
Abbreviations: BMI, body mass index; IBD, inflammatory bowel disease; ALT, alanine aminotransferase, AST, aspartate aminotransferase; Alk P, 
alkaline phosphatase; INR, international normalized ratio; MELD, model for end-stage liver disease; N/A, not applicable.
¶
p-value<0.05
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Table 2
Summary of significant and trending biochemical changes observed when comparing serum from patients 
with primary biliary cirrhosis (PBC; n=18), primary sclerosing cholangitis (PSC; n=21), and healthy controls 
(n=10). The directionality of changes is also indicated in red (increase) or green (decrease).
PBC
Control
PSC
Control
PSC
PBC
Total biochemicals p≤0.05 101 115 56
Biochemicals
(↑↓) 61|40 67|48 19|37
Total biochemicals 0.05<p<0.10 40 30 29
Biochemicals
(↑↓) 23|17 16|14 16|13
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Table 3
Alterations in free fatty acids when comparing patients with primary biliary cirrhosis (PBC), primary 
sclerosing cholangitis (PSC), and healthy controls. Trending (0.05<p<0.10) or significant (p≤0.05) elevations 
are denoted by pink and red shading, respectively, while trending or significant reductions are indicated by 
light green and dark green shading, respectively.
Sub Pathway Biochemical Name PBCHC
PSC
HC
PSC
PBC
Medium Chain Fatty Acid
caproate (6:0) 1.26 1.12 0.89
10-undecenoate (11:1n1) 1.32 1.65 1.25
5-dodecenoate (12:1n7) 1.75 1.78 1.02
Long Chain Fatty Acid
myristoleate (14:1n5) 2.32 2.29 0.99
pentadecanoate (15:0) 1.28 1.2 0.94
palmitate (16:0) 1.31 1.28 0.98
palmitoleate (16:1n7) 2.17 2.01 0.93
margarate (17:0) 1.37 1.23 0.9
10-heptadecenoate (17:1n7) 2.12 1.81 0.85
oleate (18:1n9) 1.84 1.82 0.99
Cis-vaccenate (18:1n7) 1.79 1.5 0.84
nonadecanoate (19:0) 1.33 1.14 0.86
10-nonadecenoate (19:1n9) 1.87 1.7 0.91
eicosenoate (20:1n9 or 11) 1.97 1.65 0.84
Polyunsaturated Fatty Acid (n3 and n6)
stearidonate (18:4n3) 1.54 1.63 1.06
docosapentaenoate (n3 DPA; 22:5n3) 1.45 1.37 0.94
docosahexaenoate (DHA; 22:6n3) 1.27 1.38 1.09
linoleate (18:2n6) 1.69 1.66 0.99
linolenate [alpha or gamma; (18:3n3 or 6)] 1.74 1.84 1.06
docosapentaenoate (n6 DPA; 22:5n6) 1.67 1.49 0.89
docosadienoate (22:2n6) 1.73 1.54 0.89
dihomo-linoleate (20:2n6) 1.55 1.54 0.99
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Table 4
Differential alterations in free amino acids, dipeptides, and fibrinogen cleavage peptides when comparing 
patients with primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and healthy controls. 
Trending (0.05<p<0.10) or significant (p≤0.05) elevations are denoted by pink and red shading, respectively, 
while trending or significant reductions are indicated by light green and dark green shading, respectively.
Sub Pathway Biochemical Name PBCHC
PSC
HC
PSC
PBC
Free Amino Acid
serine 1.11 0.84 0.76
aspartate 1.28 0.89 0.69
glutamate 1.44 0.98 0.68
histidine 0.99 0.91 0.91
phenylalanine 1.2 1.06 0.88
ornithine 1.13 0.68 0.61
Dipeptide
aspartylphenylalanine 1.45 0.71 0.49
cyclo(phe-phe) 1.08 0.69 0.64
glycylglycine 1.12 1.64 1.47
glycylphenylalanine 0.73 0.42 0.58
glycylvaline 2.98 0.55 0.18
histidyltryptophan 1.67 0.53 0.32
leucylalanine 0.62 1.03 1.67
leucylleucine 0.66 0.39 0.59
leucylphenylalanine 0.37 0.3 0.82
phenylalanylleucine 1.47 0.81 0.55
phenylalanylphenylalanine 1.63 0.94 0.58
phenylalanylserine 1.33 2.07 1.56
phenylalanyltryptophan 0.69 0.55 0.8
pyroglutamylglycine 1.7 1.1 0.65
tryptophylglutamate 1.96 0.9 0.46
valylarginine 0.89 1.37 1.53
Fibrinogen Cleavage Peptide
ADSGEGDFXAEGGGVR* 1.45 1.9 1.32
DSGEGDFXAEGGGVR* 0.99 3.86 3.9
ADpSGEGDFXAEGGGVR* 0.38 0.91 2.42
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